reports hero background
Updated: Sep 27, 2026
ENLV Logo

Enlivex

NASDAQ:ENLV·Stock Analysis Report
Day Range
$0.38 - $0.43
Market Cap
10.84M
P/E Ratio
0.0016
Avg Value
$13.81
Year Range
$0.47 - $27.15
$0.39-$0.04 (-8.37%)
1
General Information
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis.

Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

2
Enlivex (ENLV) Stock Graph
3
How We Grade Enlivex (ENLV)

We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.

The chart below shows how we grade Enlivex (ENLV) across the board compared to its closest peers.

4
Benzinga Edge Rankings

Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.

5
Peer Ratings

See how Enlivex compares to its peers in these key performance metrics from Benzinga Rankings.

Top Peers
Value
Quality
Growth
Momentum
Short
Medium
Long
KALAKala Bio
N/A
N/A
N/A
N/A
GDTCCytoMed Therapeutics
N/A
N/A
N/A
N/A
MTVAMetaVia
N/A
N/A
N/A
N/A
SNTISenti Biosciences
N/A
N/A
N/A
N/A
Short: price trend over the last couple of months
Medium: price trend over the last couple of quarters
Long: price trend over the past year
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
6
Past Performance
How has Enlivex (ENLV) performed over the past 5 years?

The two main factors that we consider when analyzing past performance is overall return and volatility

Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.

This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.

Enlivex (ENLV) sharpe ratio over the past 5 years is -0.0310 which is considered to be below average compared to the peer average of -0.0171